✦ LIBER ✦

Nilotinib for imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: A single- and multiple-dose, open-label pharmacokinetic study in Chinese patients

✍ Scribed by Li Zhou; Fanyi Meng; Ophelia Yin; Jianxiang Wang; Ying Wang; Yongqiang Wei; Pei Hu; Zhixiang Shen

Book ID: 113544003
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 819 KB
Volume: 31
Category: Article
ISSN: 0149-2918
DOI: 10.1016/j.clinthera.2009.07.016

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Nilotinib in imatinib-resistant or imati

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study

✍ Giles, F J; le Coutre, P D; Pinilla-Ibarz, J; Larson, R A; Gattermann, N; Ottman 📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 383 KB

Expanding Nilotinib Access in Clinical T

Expanding Nilotinib Access in Clinical Trials (ENACT) : An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase

✍ Franck E. Nicolini; Anna Turkina; Zhi-Xiang Shen; Neil Gallagher; Saengsuree Joo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB 👁 2 views

## Abstract ## BACKGROUND: Nilotinib is a selective, potent BCR‐ABL inhibitor. Previous studies demonstrated the efficacy and safety of nilotinib in Philadelphia chromosome‐positive chronic myeloid leukemia patients in chronic phase (CML‐CP) or accelerated phase who failed prior imatinib. ## METH

Pilot study of lonafarnib, a farnesyl tr

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

✍ Gautam Borthakur; Hagop Kantarjian; George Daley; Moshe Talpaz; Susan O'Brien; G 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 2 views

Dasatinib in imatinib-resistant or imati

Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study : Efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily

✍ Giuseppe Saglio; Andreas Hochhaus; Yeow Tee Goh; Tamas Masszi; Ricardo Pasquini; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 373 KB 👁 1 views